Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insur Regulatory News (SBRE)

Share Price Information for Sabre Insur (SBRE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 156.00
Bid: 156.00
Ask: 158.00
Change: -2.00 (-1.27%)
Spread: 2.00 (1.282%)
Open: 159.00
High: 159.00
Low: 156.00
Prev. Close: 158.00
SBRE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

14 May 2021 07:00

RNS Number : 5928Y
Sabre Insurance Group PLC
14 May 2021
 

 

14 May 2021

SABRE INSURANCE GROUP PLC

 

Trading Update

 

Sabre Insurance Group plc (the "Group" or "Sabre"), one of the UK's leading private motor insurance underwriters, today provides an update on trading for the period to 30 April 2021 ahead of its AGM later this morning.

- Continued focus on prioritising underwriting profitability over volume, with price increases materially ahead of the market

- Overall, volumes for the first quarter of the year are in line with our expectations

- Gross written premium for the four months to 30 April 2021 was £46.0m (four months to 30 April 2020: £54.6m)

- Continued strong organic capital generation with a solvency coverage ratio of 171% post-dividend as at 31 March 2021 (31 December 2020: 155%)

- Too early to identify meaningful market quote volume increases as lockdown eases, however:

- throughout April, volumes were ahead of the comparative period in 2020

- clear visibility on premium outturn for the full year remains limited at this point due to numerous intertwined regulatory, market and COVID impacts

- combined ratio for the financial year is expected to be within the target range of 70% to 80%

 

Geoff Carter, Chief Executive Officer of Sabre, commented:

"Volumes through Q1 were in line with our expectations, during which we continued to execute our strategy of focusing on profitability over volume. Alongside that, we continue to investigate and implement new rating factors and potential new, complementary product offerings which will help drive disciplined and profitable volume growth in future periods.

While we are still in the very early stages of an easing in the lockdown restrictions, through April we have started to see some increase in our premium levels, and the policy count has enjoyed modest growth. Premiums in April were 14.6% higher than the same period last year, with the weekly run-rate increasing relative to 2020 towards the end of the month and into the first week of May. This is despite us being consistent with regard to our pricing discipline and against a backdrop of low quote volumes across the market.

Looking forward, we remain confident that volumes will increase as the number of drivers and car sales increase. We also expect that - in due course - the FCA pricing review, changes to small bodily injury claims ("whiplash reforms") and ongoing claims inflation will drive some competitors to increase prices materially.

Our claims performance and organic capital generation was strong, and we remain confident of providing an attractive dividend for the year, possibly through the utilisation of our robust capital range. While short term visibility remains limited, we remain confident that our agility and tried-and-tested strategy will deliver a strong result for the year.

Finally, we are delighted to have appointed Matthew Wright as our new Chief Actuary after a near 12-month transition period and seven years with Sabre. We are confident Matt will be able to further enhance our market leading pricing capabilities."

 

Investor enquiries

01306 747272

Sabre Insurance Group plc

Geoff Carter / Adam Westwood

Media enquiries

020 7353 4200

Tulchan Communications

sabre@tulchangroup.com

James Macey White

David Allchurch

Giles Kernick

The Sabre Insurance Group plc LEI number is 2138006RXRQ8P8VKGV98

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBUGDUSXBDGBX
Date   Source Headline
23rd Apr 20244:00 pmRNSHolding(s) in Company
22nd Apr 20243:22 pmRNSHolding(s) in Company
19th Apr 20248:51 amRNSChair Appointment
18th Apr 202411:22 amRNSDirector Declaration
11th Apr 202412:41 pmRNSDirector/PDMR Shareholding
11th Apr 202412:07 pmRNSDirector/PDMR Shareholding
9th Apr 20242:44 pmRNSDirector/PDMR Shareholding
5th Apr 20243:48 pmRNSNotice of AGM
21st Mar 202412:30 pmRNSDirector/PDMR Shareholding
19th Mar 20247:00 amRNSFull-year results 2023
13th Mar 20249:33 amRNSNotice of Results
12th Mar 20242:16 pmRNSDirector/PDMR Shareholding
12th Mar 202412:14 pmRNSDirector Declaration
16th Feb 20241:52 pmRNSHolding(s) in Company
15th Feb 20247:00 amRNSTrading Statement
13th Feb 20242:18 pmRNSDirector/PDMR Shareholding
11th Jan 202411:11 amRNSDirector/PDMR Shareholding
20th Dec 20232:24 pmRNSHolding(s) in Company
12th Dec 202312:03 pmRNSDirector/PDMR Shareholding
28th Nov 20234:27 pmRNSDirectorate Change
27th Nov 20234:42 pmRNSRemuneration Committee Chair Appointment
22nd Nov 20238:51 amRNSNotification of cyber incident
20th Nov 20237:00 amRNSDeath of Chair
13th Nov 202311:44 amRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSTrading Update
11th Oct 202312:52 pmRNSDirector/PDMR Shareholding
25th Sep 20233:39 pmRNSDirector/PDMR Shareholding
21st Sep 202311:48 amRNSDirector/PDMR Shareholding
14th Sep 20232:25 pmRNSHolding(s) in Company
13th Sep 202310:00 amRNSDirector/PDMR Shareholding
13th Sep 20239:33 amRNSDirectorate Change
11th Aug 202310:07 amRNSDirector/PDMR Shareholding
3rd Aug 20237:00 amRNSHalf-year Report 2023
25th Jul 20238:53 amRNSDirector Declaration
11th Jul 20232:57 pmRNSDirector/PDMR Shareholding
13th Jun 202310:09 amRNSDirector/PDMR Shareholding
2nd Jun 20233:02 pmRNSDirector/PDMR Shareholding
25th May 202311:22 amRNSResult of AGM
25th May 20239:27 amRNSDirector/PDMR Shareholding
25th May 20237:01 amRNSBoard Appointment
25th May 20237:00 amRNSTrading Update
11th May 202311:42 amRNSDirector/PDMR Shareholding
18th Apr 20233:19 pmRNSDirector/PDMR Shareholding
12th Apr 202311:53 amRNSDirector/PDMR Shareholding
6th Apr 202312:28 pmRNSDirector/PDMR Shareholding
31st Mar 20233:43 pmRNSNotice of AGM
31st Mar 20233:37 pmRNSDirector/PDMR Shareholding
14th Mar 20237:00 amRNSFinal Results
13th Mar 202312:13 pmRNSDirector/PDMR Shareholding
13th Feb 20231:51 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.